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Summary 
Autosomal dominant polycystic kidney disease 
(ADPKD) is a common genetic disorder that frequently 
results in renal failure due to progressive cyst develop- 
ment. The major locus, PKD7, maps to 16~13.3. We 
identified a chromosome translocation associated 
with ADPKD that disrupts a gene (PBP) encoding a 14 
kb transcript in the PKD7 candidate region. Further 
mutations of the PBP gene were found in PKD7 Pa- 
tients, two deletions (one a de novo event) and a splic- 
ing defect, confirming that PBP Is the PKD7 gene. This 
gene is located adjacent to the TSCP locus in a geno- 
mic region that is reiterated more proximally on 16~. 
The duplicate area encodes three transcripts substan- 
tially homologous to the PKD7 transcript. Partial se- 
quence analysis of the PKD7 transcript shows that it 
encodes a novel protein whose function is at present 
unknown. 
Introduction 
A landmark study by Dalgaard (1957) showed that autoso- 
mal dominant polycystic kidney disease (ADPKD), also 
termed adult polycystic kidney disease, is one of the most 
common genetic diseases in humans (approximately 1 in 
1000 individuals affected). The major feature of this dis- 
ease is the development of cystic kidneys that commonly 
leads to renal failure in adult life. This simple description, 
however, belies the diverse clinical phenotype of ADPKD, 
which is now considered a systemic disorder (reviewed 
by Gabow, 1990) and one that occasionally presents in 
childhood(Finket al., 1993; Zerreset al., 1993). Extrarenal 
manifestations include liver cysts (Milutinovic et al., 1960) 
and (more rarely) cysts of the pancreas (Gabow, 1993) 
and other organs. Intracranial aneurysms occur in approxi- 
mately 5% of patients and are a significant cause of mor- 
bidity and mortality due to subarachnoid hemorrhage 
(Chapman et al., 1992). More recently, an increased prev- 
alence of cardiac valve defects (Hossack et al., 1988) 
herniae (Gabow, 1990), and colonic diverticulae (Scheff 
et al., 1980) has been reported. 
The major cause of morbidity in ADPKD, however, is 
progressive renal disease characterized by the formation 
and enlargement of fluid-filled cysts, resulting in grossly 
enlarged kidneys. Renal function deteriorates as normal 
tissue is compromised by cystic growth, resulting in end 
stage renal disease (ESRD) in more than 500/b of patients 
by the age of 60 years (Gabow et al., 1992): ADPKD ac- 
counts for 8%~loo/, of all renal transplantation and dial- 
ysis patients in Europe and the United States (Gabow, 
1993). Biochemical studies have suggested several poten- 
tial causes of cyst formation and development, including 
abnormal epithelial cell growth, alterations to the extracel- 
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Figure 1. A Chromosome Translocation Associated with PKD7 
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(a) (Top) A long-range map of the terminal region of the short arm of chromosome 16 showing the PKD7 candidate region defined by genetic 
linkage analysis. The positions of selected DNA probes and microsatellites used for haplotype, linkage, or heterozygosity analysis are indicated. 
Markers previously described in linkage disequilibrium studies are shown in bold (adapted from Harris et al., 1990, 1991; Germino et al., 1992; 
Somlo et al., 1992; Peral et al., 1994; Snarey et al., 1994). (Bottom) A detailed map of the distal part of the PKDl candidate region showing the 
area of 16~13.3 duplicated in 16~13.1 (hatched); Clal restriction sites (C); the breakpoints in the somatic cell hybrids N-OH1 and P-MWH2A; DNA 
probes; and the TSCP gene. The limits of the position of the translocation breakpoint found in family 77 (see [b]), determined by evidence of 
heterozygosity (in 774) and by PFGE (see [c] and text) is also indicated. The contig covering the family 77 breakpoint region consists of the 
following cosmids: I, CWSD; 2, ZDSS; 3, JH2A; 4, REP59; 5, X10.26; 6, CWlO///; 7, SM25A; 8, SMII; 9, NM1 7. 
(b) Pedigree of family 77, which segregates a 16;22 translocation, showing the chromosomal composition of each subject. Individuals 77-2 and 
77-3 have the balanced products of the exchange and have PKD7; 774 is monosomic for 16pl3.3*16pter and 22q11.21’22pter and has TSC. 
(c) PFGE of DNA from members of family 77: 77-l (I), 77-2 (2) 773 (3) and 77-4 (4) digested with Clal and hybridized with SM6. In addition to 
the normal fragments of 340 kb and partially digested fragment of 480 kb, a proximal breakpoint fragment of approximately 100 kb (shown by 
arrow) is seen in individuals 77-2, 77-3, and 77-4, concordant with segregation of the der(16) chromosome. 
lular matrix, and changes in cellular polarity and secretion 
(reviewed by Gabow, 1991; Wilson and Sherwood, 1991). 
The primary defect in ADPKD, however, remains unclear, 
and considerable effort has therefore been applied to iden- 
tifying the defective gene(s) in this disorder by genetic 
approaches. 
The first step toward positional cloning of an ADPKD 
gene was the demonstration of linkage of one locus, now 
designated as the polycystic kidney disease 1 (PKD7) lo- 
cus, to the a-globin cluster on the short arm of chromo- 
some 16 (Reeders et al., 1985). Subsequently, families 
with ADPKD unlinked to markers of 18p were described 
(Kimberlinget al., 1988; Romeoet al., 1988) andasecond 
ADPKD locus (PKD2) has recently been assigned to chro- 
mosome region 4q13-q23 (Kimberling et al., 1993; Peters 
et al., 1993). It is estimated that approximately 85% of 
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Figure 2. FISH of Cosmid from the Duplicated 
Area to a Normal Male Metaphase 
Duplication of the locus CWlOlll (cosmid 6 in 
Figure la) is illustrated with two sites of hybrid- 
ization on 16~; the distal site (the PKDI region) 
is shown by an arrow. The signal from the proxi- 
mal site (16~13.1) is stronger than that from 
the distal, indicating that sequences homolo- 
gous to CWlO/// are reiterated in 16~13.1. 
ADPKD is due to PKD7 (Peters and Sandkuijl, 1992) with 
PKDP accounting for most of the remainder. PKDPappears 
to be a milder condition with a later age of onset and ESRD 
(Parfrey et al., 1990; Gabow et al., 1992; Ravine et al., 
1992). 
The position of the PKD7 locus was refined to chromo- 
some band 16~13.3, and many markers were isolated from 
that region (Breuning et al., 1967, 1990; Reeders et al., 
1966; Germino et al., 1990; Hyland et al., 1990; Himmel- 
bauer et al., 1991). Their order and the position of the 
PKD7 locus have been determined by extensive linkage 
analysis in normal and PKD7 families and by the use of 
a panel of somatic cell hybrids (Reeders et al., 1966; 
Breuning et al., 1990; Germino et al., 1990). An accurate 
long range restriction map (Harris et al., 1990; Germino 
et al., 1992) has located the PKD7 locus in an interval of 
approximately 600 kb between the markers G G G 7  and 
SM7 (Harris et al., 1991; Somlo et al., 1992) (see Figure 
1 a). The density of CpG islands and identification of many 
mRNA transcripts indicated that this area is rich in gene 
sequences. Germino et al. (1992) estimated that the candi- 
date region contains approximately 20 genes. 
Identification of the PKD7 gene from within this area 
has thus proved difficult, and other means to pinpoint the 
disease gene were sought. Linkage disequilibrium has 
been demonstrated in a Scottish population between 
PKD7 and the proximal marker VK5 (Pound et al. , 1992) 
and in a Spanish population between PKD7 and BLu24 
(see Figure 1 a) (Peral et al., 1994). Studies with additional 
markers have shown evidence of a common ancestor in 
a proportion of each population (Peral et al., 1994; Snarey 
et al., 1994) but the association has not precisely posi- 
tioned the PKD7 locus. 
Disease-associated genomic rearrangements, detected 
by cytogenetics or pulsed-field gel electrophoresis (PFGE), 
have been instrumental in the identification of the genes 
associated with many genetic disorders. In the case of the 
tuberous sclerosis (TSC) locus TSCP, which lies within 
16~13.3, deletions were detected by PFGE, within the in- 
terval thought to contain the PKD7 gene, and their char- 
acterization was a significant step toward the rapid identi- 
fication of the TSC2 gene (European Chromoso’me 16 
Tuberous Sclerosis Consortium, 1993). 
We have now identified a pedigree in which the two 
distinct phenotypes, typical ADPKD or TSC, are seen in 
different members. In this family the two individuals with 
ADPKD are carriers of a balanced chromosome transloca- 
tion with a breakpoint within 16~13.3. We have located 
the chromosome 16 translocation breakpoint, and a gene 
disrupted by this rearrangement has been defined; the 
discovery of additional mutations of that gene in other 
PKD7 patients shows that we have identified the PKD7 
gene. 
Results 
A Translocation Associated with ADPKD 
A major pointer to the identity of the PKD7 gene was pro- 
vided by a Portuguese pedigree (family 77) with both 
ADPKD and TSC (Figure 1 b). Cytogenetic analysis showed 
that the mother, 77-2, has a balanced translocation, 46XX 
t(l6;22)(p13.3;qll.21), that was inherited by her daughter, 
77-3. The son, 774, has the unbalanced karyotype 45XYI 
- 16-22+der(16)(16qter+16p13.3::22q11.21+22qter) and 
consequently is monosomic for 16~13.3~16pter as well 
as for 22qll.21+22pter. This individual has the clinical 
phenotype of TSC (see Experimental Procedures); the 
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Figure 3. A Detailed Map of the PBP Gene Region Showing the Family 77 Translocation Breakpoint 
(a) A detailed map of the translocation region showing the precise localization of the family 77 breakpoint and the region that is duplicated in 
16~13.1 (hatched). DNA probes (open boxes), the transcripts PBP and TSC2 (closed boxes; with direction of transcription indicated by an arrow), 
and cDNAs (stippled boxes) are shown below the genomic map. The known genomic extent of each gene is indicated at the bottom of the dlagram, 
and the approximate genomic locations of each cDNA are indicated under the genomic map. The positions of genomic deletions found in P/CD7 
patients OX875 and OX1 14 are also indicated. Restriction sites for EcoRl (E) and incomplete maps for BamHl (B), Sac1 (S), and Xbal (X) are 
shown. 
(b) Southern blots of BamHI-digested DNA from individuals 77-1 (I), 77-2 (2) and 77-4 (4) hybridized with 8S3 (left) and 8S7 (right) (see [a]). 8S3 
detects a novel fragment on the telomeric side of the breakpoint (12 kb; shown by arrow), associated with the der(22) chromosome in 77-2, but 
not 77-4; 8.97 identifies a novel fragment on the centromeric side of the breakpoint (9 kb; shown by arrow), associated with the der(16) chromosome 
in 77-2 and 77-4. The telomeric breakpoint fragment is also seen weakly with 8.91 (shown by arrow), indicating that the breakpoint lies in the distal 
part of 8Sl. The 8S3 and 8Sl loci are both duplicated; the normal BamHl fragment detected at the 16~13.3 site by these probes is 11 kb (see 
[a]), but a similarly sized fragment is also detected at the 16~13.1 site. Consequently, the breakpoint fragments are much fainter than the normal 
(16~13.1 plus 16~13.3) band. 
most likely explanation was that the TSC2 locus located disrupted the PKDl locus in 16~13.3 and proceeded to 
within 16~13.3 was deleted in the unbalanced karyotype. identify and clone the region containing the breakpoint. 
Further analysis revealed that the mother (77-2) and the 
daughter (77-3) with the balanced translocation have the 
clinical features of ADPKD (see Experimental Proce- 
dures), while the parents of 77-2 (aged 67 and 82 years) 
were cytogenetically normal, with no clinical features of 
TSC and no renal cysts on ultrasound examination. Al- 
though kidney cysts can be a feature of TSC, no other 
clinical signs of TSC were identified in 77-2 or 77-3, making 
it unlikely that the polycystic kidneys were due to TSC. We 
therefore investigated the possibility that the translocation 
Family 77 was analyzed with polymorphic markers from 
16~13.3. Individual 77-4 was hemizygous for MS2052 and 
GGGl,  but heterozygous for SM6and more proximal mark- 
ers, locating the translocation breakpoint between G G G 7  
and SM6 (see Figure la). Fluorescence in situ hybridiza- 
tion (FISH) of a cosmid from the TSC2 region, CWSD (cos- 
mid 1 in Figure la), to metaphase spreads showed that 
it hybridized to the der(22) chromosome of 77-2, placing 
the breakpoint proximal to CWSD and indicating that 77-4 
was hemizygous for this region, consistent with his TSC 
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phenotype. DNA from members of family 77 was digested 
with Clal, separated by PFGE, and hybridized with SM6, 
revealing a breakpoint fragment of - 100 kb in individuals 
with theder(l6)chromosome(Figure lc). Thesmall sizeof 
this novel fragment enabled the breakpoint to be localized 
distal to SM6 in a region of just 60 kb (Figure 1 a). A cosmid 
contig covering this region was therefore constructed (see 
Experimental Procedures for details). 
The Translocatlon Breakpoint Lies within a Region 
Duplicated Elsewhere on Chromosome 16 
(16P13.1) 
It was previously noted that the region between CW27 and 
N54 (Figure la) was duplicated at a more proximal site 
on the short arm of chromosome 16 (Germino et al., 1992; 
European Chromosome 16 Tuberous Sclerosis Consor- 
tium, 1993). Figure 2 shows that a cosmid, CWO///, from 
the duplicated region hybridizes to two points on 16~: the 
distal PKD7 region and a proximal site positioned in 
16~13.1. The structure of the duplicated area is complex, 
with each fragment present once in 16~13.3 reiterated two 
to four times in 16~13.1 (see Figure 2). Cosmids spanning 
the duplicated area in 16~13.3 were subcloned (see Figure 
3a; see Experimental Proceduresfordetails), and a restric- 
tion map was generated. A genomic map of the PKD7 region 
was constructed using a radiation hybrid, Hy745.79, that 
contains the distal portion of 16~ but not the duplicate site 
in 16~13.1. 
To localize the family 77 translocation breakpoint, sub- 
clones from the target region were hybridized to DNA from 
patient 77-2, digested with Clal, and separated by PFGE. 
Once probes mapping across the breakpoint were identi- 
fied, they were hybridized to conventional Southern blots 
of family 77 DNA. Figure 3b shows that novel BamHl frag- 
ments were detected from the centromeric and telomeric 
side of the breakpoint, which was localized to the distal 
part of the probe 8S7 (Figure 3a). Hence, the balanced 
translocation was not associated with a substantial dele- 
tion, and the breakpoint was located more than 20 kb proxi- 
mal to the TSC2 locus (Figure 3a). These results supported 
the hypothesis that ADPKD in individuals with the bal- 
anced translocation (77-2 and 77-3) was not due to disrup- 
tion of the TSCP gene, but indicated that a separate gene 
mapping just proximal to TSC2 was likely to be the PKD7 
gene. 
The Polycystic Breakpoint Gene Is Disrupted 
by the Translocation 
Localization of the family 77 breakpoint identified a precise 
region in which to look for a candidate for the PKD7 gene. 
During the search for the TSC2 gene, we identified other 
transcripts not associated with TSC, including a large tran- 
script (- 14 kb) partially represented in the cDNAs 3A3 
and AH4 that mapped to the genomic fragments CW23 
and CW27 (Figure 3a). The orientation of the gene encod- 
ing this transcript had been determined by the identifica- 
tion of a poly(A) tract in the cDNA, AH4: the 3’ end of 
this gene lies very close to the TSC gene, in a tail-to-tail 
orientation (European Chromosome 16 Tuberous Sclero- 
sis Consortium, 1993). To determine whether this gene 
crossed the translocation breakpoint, genomic probes 
from within the duplicated areaand flanking the breakpoint 
were hybridized to Northern blots. Probes from both sides 
of the breakpoint, between JH5 and JH73, identified the 
14 kb transcript (Figure 3a; see below for details). There- 
fore, this gene (previously called 3A3, but now designated 
the polycystic breakpoint [PBP] gene) extended over the 
family 77 breakpoint and consequently was a candidate 
for the PKD7 gene. A walk was initiated to increase the 
extent of the PBP cDNA contig, and several novel cDNAs 
were identified using probes from the single copy (nondu- 
plicated) region (see Experimental Procedures for details). 
A cDNA contig was constructed that extended -5.7 kb, 
including - 2 kb into the area that is duplicated (Figure Sa). 
Expression of the PBP Gene 
Initial studies of the expression pattern of the PBP gene 
were undertaken with cDNAs that map entirely within the 
single copy region (e.g., AH4 and 3A3). Figure 4a shows 
that the - 14 kb transcript was identified by 3A3 in various 
tissue-specific cell lines. From this and other Northern 
blots, we concluded that the PBP gene was expressed in 
all of the cell lines tested, although often at a low level. 
The two cell lines that showed the highest level of expres- 
sion were fibroblasts and a cell line derived from an astro- 
cytoma, G-CCM. Significant levelsof expression were also 
obtained in cell lines derived from kidney (G401) and liver 
(Hep3B). Measuring the expression of the PBP gene in 
tissue samples by Northern blotting proved difficult be- 
cause such a large transcript is susceptible to minor RNA 
degradation. However, initial results with an RNAase pro- 
tection assay, using a region of the gene located in the 
single copy area (see Experimental Procedures), showed 
a moderate level of expression of the PBP gene in tissue 
obtained from normal and polycystic kidney (data not 
shown). The widespread expression of the PBP gene is 
consistent with the systemic nature of ADPKD. 
Identification of Transcripts That Are Partially 
Homologous to the PBP Transcript 
Novel cDNAs were identified with the genomic fragments, 
JH4 and JH8, that map to the duplicated region (see Figure 
3a; see Experimental Procedures). However, when these 
cDNAs were hybridized to Northern blots, a more complex 
pattern than that seen with 3A3 was observed. As well as 
the - 14 kb PBP transcript, three other partially homolo- 
gous transcripts were identified, designated homologous 
gene A (HG-A) (-21 kb), HG-B (- 17 kb), and HG-C (6.5 
kb) (Figure 4b). There were two possible explanations for 
these results: either the HG transcripts were alternatively 
spliced forms of the PBP gene, or the HG transcripts were 
encoded by genes located in 16~13.1. To determine the 
genomic location of the HG loci, a fragment from the 3’ 
end of one HG cDNA (HG-4/7.7) was isolated. HG-4/7.7 
hybridized to all three HG transcripts, but not to the PBP 
transcript, and on a hybrid panel it mapped to 16~13.1 
(not the PKD7 area). These results show that all the HG 
transcripts are related to each other outside the region of 
homology with the PBPtranscript and that the HG loci map 
to the proximal site (16~13.1). 
C&l 
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1 234567 8 9 kb 
blot containing - 1 ug of poly(A)-selected 
mRNA per lane of the tissue-specific cell lines: 
lane 1, MJ, Epstein-Barr virus-transformed 
lymphocytes; lane 2, K582, erythroleukemia; 
lane 3, FSl, normal fibroblasts; lane 4, HeLa. 
PBP cervical carcinoma; lane 5, G401, renal Wilm’s 
tumor; lane 8, Hep3B, hepatoma; lane 7, HT29, 
colonic adenocarcinoma; lane 8, SW13, adre- 
-9.5 nal carcinoma: lane 9, G-CCM, astrocytoma. 
A single transcript of approximately 14 kb is 
-7.5 seen; the highest level of expression is in fibro- 
blasts and in the astrocytoma cell line G-CCM. 
Although in this comparative experiment little 
expression is seen in lanes 1,4. and 7, we have 
demonstrated at least a low level of expression 
in these cell lines on other Northern blots and 
8S1 by RT-PCR (see later). 
Figure 4. Northern Blot Analysis of the PBP 
Transcript 
(a) PBP cDNA, 3A3, hybridized to a Northern 
b 
(b) A Northern blot containing - 20 ug of total 
3A3 JH8 21P.9 
HG-A 
HG-B 
i PBP 
-. - HG-C 
N 2 4 
RNA from cell line G-CCM hybridized with 
cDNAs or a genomic probe that each identify 
different parts of the PBP gene. (Left) A single 
- 14 kb transcript is seen with a cDNA from 
the single copy area, 3A3. (Right) A cDNA. 
PBP 21P.9, that is homologous to parts of the region 
that is duplicated (J/412, JH8. and J/-/70; see 
Figure 3a) hybridizes to the PBP transcript and 
three novel transcripts: HG-A (- 21 kb), F/G-B 
PBP-77 (- 17 kb), and HG-C (8.5 kb). A similar pattern 
of transcripts is seen with cDNAs and genomic 
fragments that hybridize to the area between 
JH5 and JHi3, with the exception of the JH8 
area. (Middle) JH8 hybridizes to the transcripts 
PBP, HG-A, and HG-B but not to I-/G-C. 
(c) A Northern blot of 20 ug of total fibroblast RNA from normal control (N), 77-2 (2) and 77-4 (4) hybridized with 8S7, which contains the 16;22 
translooation breakpoint (see Figure 3). A transcript of -9 kb (PBP-77) is identified in the two patients with this translocation, but not in the normal 
control. PBf-77 is a chimeric PBP transcript formed owing to the translocation and is not seen in RNA from 77-2 or 77-4 with probes that map 
distal to the breakpoint. 
An Abnormal Transcript Associated 
with the Family 77 Translocation 
As the PBP gene was transcribed across the region dis- 
rupted by the family 77 translocation breakpoint, in a proxi- 
mal to distal direction on the chromosome (see Figure 3a), 
it was possible that a novel transcript originating from the 
PBP promotor would be found in this family. Figure 4c 
shows that using a probe to the PBP transcript that 
mapped mainly proximal to the breakpoint, a novel tran- 
script of approximately 9 kb (PBP-77) derived from the 
der(16) product of the translocation was detected. Interest- 
ingly, the PBP-77 transcript appears to be expressed at a 
higher level than the normal product of PBP. These results 
confirmed that the family 77 translocation disrupts the PBP 
gene and supports the hypothesis that this is the PKDl 
gene. 
Mutations of the PBP Gene 
in Other ADPKD Patients 
To prove that the PBP gene is the defective gene at the 
PKD7 locus, we analyzed this region for mutations in pa- 
tients with typical ADPKD. The 3’end of the PBPgene was 
most accessible to study as it maps outside the duplicated 
area. To screen this region, BamHl digests of DNA from 
262 apparently unrelated ADPKD patients were hybridized 
with the probe 7A7H6(see Figure 3a). In addition, a large 
EcoRl fragment (41 kb) that contains a significant propor- 
tion of the PBP gene was assayed by field inversion gel 
electrophoresis (FIGE) in 167 ADPKD patients, using the 
probe CW70. Two genomic rearrangements were identi- 
fied in ADPKD patients by these procedures, each identi- 
fied by both methods. 
The first rearrangement was identified in patient OX675 
(see Experimental Procedures for clinical details), who 
was shown to have a 5.5 kb genomic deletion within the 
3’ end of the PBP gene (for details see Figures 5a and 5b 
and Figure 3a). This genomic deletion results in an -3 
kb internal deletion of the transcript (PBP-875), with the 
-500 bp adjacent to the poly(A) tail intact. In this family, 
linkage of ADPKD to chromosome 16 could not be proven 
because although OX675 has a positive family history of 
ADPKD, there were no living, affected relatives. However,  
paraff in-embedded tissue from her affected father (now 
deceased) was available. We demonstrated, using the 
polymerase chain reaction (PCR), amplification of a 220 
bp fragment spanning the deletion (data not shown), and 
hence that this individual had the same rearrangement as 
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Figure 5. Analysis of lntragenic Mutations of the PBP Gene 
(a) FIGE of DNA from normal (N) and ADPKD patient OX875 (875) digested with EcoRl and hybridized with CW70 (left) and J/-/1 (middle). Normal 
fragments of 41 kb (plus a 31 kb fragment from the 16~13.1 site) (CW70) and 16 kb (J/+1) are identified with these probes; OX875 has an additional 
53 kb band (shown by arrow). The EcoRl site separating these two fragments is removed by the deletion (see Figure 3a). The right panel shows 
a Southern blot of BamHI-digested DNA (as above) hybridized with 1AfH.6. A novel fragment of 9.5 kb is seen in DNA from 0X675, as well as 
the normal 15 kb fragment. These results indicate that OX875 has a 5.5 kb deletion: its position was determined more precisely by mapping 
relative to two Xbal sites that flank the deletion (see Figure 3a). 
(b) Northern blot of total fibroblast RNA, as in (a), hybridized with the cDNAs AH4, 3A3, and A/-/3. A novel transcript (PBP-875) of - 11 kb is seen 
with AH4 (the band is reduced in intensity because the probe is partly deleted) and AH3 (shown by arrow), which flank the deletion, but not 3A3, 
which is entirely deleted (see Figure 3a). The transcripts /-/G-A, HGB, and HGC. from the duplicated area, are seen with A/f3 (see Figure 4b). 
(c) (Left) FIGE of DNA from normal (N) and ADPKD patient OX1 14 (114) digested with EcoRl and hybridized with CW70; a novel fragment of 39 
kb (shown by arrow) is seen in OX1 14. (Middle) DNA, as above, plus the normal mother(M) and brother (6) of 0X114, digested with BamHl and 
hybridized with CW27. A larger than normal fragment of 19 kb (shown by arrow) was detected in 0X114, but not other family members, owing to 
deletion of a BamHl site; together these results are consistent with a 2 kb deletion (see Figure 3a). (Right) RT-PCR of RNA, as above, with primers 
flanking the OX1 14 deletion (see Experimental Procedures). A novel fragment of 610 bp is seen in OX1 14. indicating a deletion of 446 bp in the 
PBP transcript. 
(d) RT-PCR of RNA from ADPKD patient OX32 (32) plus the probands, normal mother(M) and affected father (F), and sibs (1) and (2) using the 
C primer pair from 3A3 (see Experimental Procedures). A novel fragment of 125 bp is detected in each of the affected individuals. 
0X875. This result and analysis of two unaffected sibs of 
OX875 who did not have the deletion showed that this 
mutation was transmitted with ADPKD. 
The second rearrangement detected by hybridization 
was a 2 kb genomic deletion within the PBP gene, found 
in ADPKD patient OX1 14 (see Experimental Procedures 
for clinical details; see Figures 5c and 3a). No abnormal 
PBP transcript was identified by Northern blot analysis, 
but using primers flanking the deletion (see Experimental 
Procedures), a shortened product was detected by reverse 
transcription (RT)-PCR (Figure 5~). This was cloned and 
sequenced and shown to have a frameshift deletion of 446 
bp (between base pairs 1746 and 2192 of the sequence 
shown in Figure 7). OX1 14 is the only member of the family 
with ADPKD (she has no children), and ultrasound analysis 
of her parents at age 78 (father) and age 73 (mother) 
showed no evidence of renal cysts. Somatic cell hybrids 
were produced from OX1 14, and the deleted chromosome 
was found by haplotype analysis to be of paternal origin. 
The father of OX1 14 is now deceased, but analysis of DNA 
from the brother of OX1 14 (0X984) with seven microsatel- 
lite markers from the PKD7 region (see Experimental Pro- 
cedures) showed that he shares the same paternal chro- 
mosome, in the PKDI region, as OX1 14. Renal ultrasound 
revealed no cysts in OX984 at age 53, and no deletion 
was detected by DNA analysis (Figure 5~). Hence, the 
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Figure 6. Map of the Region Containing the TSCZ and PEP Genes Showing the Area Deleted in Patient WS-53 
Localization of the distal end of the WS-53 deletion was previously described (European Chromosome 16 Tuberous Sclerosis Consortium, 1993) 
and we have now localized the proximal end between SM6 and JH17. The size of the aberrant Mlul fragment in WS-53, detected by JHl and J-/17, 
is 90 kb, and these probes lie on adjacent Mlui fragments of 120 kb and 70 kb, respectively. Therefore, the WS-63 deletion is - 100 kb. Restriction 
sites for Mlul (M), Nrul (R), and Notl (N) and partial maps for Sacll (S) and BssHll (H) are shown. DNA probes (open boxes) and the TSCP and 
PBP transcripts (closed boxes) are indicated below the line with their known genomic extents (brackets). The locations of the microsatellites KG8 
and SM6 and the family 77 breakpoint are also indicated 
deletion in OX1 14 is a de novo event associated with the 
development of ADPKD. Although it is not possible to show 
that the ADPKD is chromosome 16 linked, the location 
of the PBP gene indicates that this is a de novo PKD7 
mutation. 
To identify more fKD7-associated mutations, we ana- 
lyzed single copy regions of the PBP gene by RT-PCR 
using RNA isolated from lymphoblastoid cell lines estab- 
lished from ADPKD patients. cDNA from 48 unrelated pa- 
tients was amplified with the primer pair 3A3 C(see Experi- 
mental Procedures), and the product of 260 bp was 
analyzed on an agarose gel. In one patient, 0X32, an 
additional smaller product (125 bp) was identified, consis- 
tent with a deletion or splicing mutation. OX32 comes from 
a large family in which the disease can be traced through 
three generations. Analysis of RNA from two affected sibs 
of OX32 and his parents showed that the abnormal tran- 
script segregates with PKD7 (Figure 5d). 
Amplification of normal genomic DNA with the 3A3 C 
primers generates a product of 418 bp; sequencing 
showed that this region contains two small introns (5’, 75 
bp; 3’, 83 bp) flanking a 135 bpexon. The product amplified 
from genomic DNA from OX32 was normal in size, exclud- 
ing agenomic deletion. However,  heteroduplex analysis of 
that DNA revealed larger heteroduplex bands, consistent 
with a mutation within that genomic interval. The abnormal 
RT-PCR product from OX32 was cloned and sequenced: 
this demonstrated that, although present in genomic DNA, 
the 135 bp exon was missing from the abnormal transcript. 
Sequencing of OX32 genomic DNA demonstrated a G-C 
transition at +l of the splice donor site following the 135 bp 
exon. This mutation was confirmed in all available affected 
family members by digesting amplified genomic DNA with 
the enzyme BstNI: a site is destroyed by the base substitu- 
tion. The splicing defect results in an in-frame deletion 
of 135 bp from the PBP transcript (3696-3831 bp of the 
sequence shown in Figure 7). Together, the three intra- 
genie mutations confirm that the PBPgene is the defective 
gene at the PKD7 locus. 
A Deletion That Disrupts the TSCP 
and the PKD7 Gene 
We previously identified a deletion (WS-53) that disrupts 
the TSCP gene and the PKD7 gene (European Chromo- 
some 16 Tuberous Sclerosis Consortium, 1993) although 
its full proximal extent was not determined. Further study 
has shown that the deletion extends - 100 kb (see Figure 
6 for details) and deletes most, if not all, of the PKD7 gene. 
This patient has TSC but also has unusually severe poly- 
cystic disease of the kidneys (full clinical details will be 
provided in a later paper). Other patients with a similar 
phenotype are presently under investigation. 
Characterization of the PKDI Gene 
To characterize the PKD7 gene further, evolutionary con- 
servation was analyzed by “zoo blotting.” Using probes 
from the single copy 3’ region (3A3) and from the dupli- 
cated area (JH4 and JH8), the PKD7 gene was conserved 
in other mammalian species, including horse, dog, pig, 
and rodents (data not shown). No evidence of related se- 
quences were seen by hybridization at normal str ingency 
in chicken, frog, or fruit fly. The degree of conservation was 
similar when probes from the single copy or the duplicated 
region were employed. 
The full genomic extent of the PKD7 gene is not yet 
known, although results obtained by hybridization to 
Northern blots show that it extends from at least as far as 
JH73. Several CpG islands have been localized 5’ of the 
known extent of the PKD7 gene (Figure 6), although there 
is no direct evidence that any of these are associated with 
this gene. 
The cDNA contig extending 5631 bp to the 3’ end of 
the PKD7 transcript was sequenced; when possible, more 
than one cDNA was analyzed, and in all regions both 
strands were sequenced (Figure 7). We estimate that this 
accounts for - 40% of the PKD7 transcript. An open read- 
ing frame was detected that runs from the 5’ end of the 
region sequenced and spans 4642 bp, leaving a 3’untrans 
lated region of 789 bp that contains the previously de- 
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Figure 7. The Partial Nucleotide Sequence of the PKDl Transcript Extending 5631 bp to the 3’ End of the Gene 
The corresponding predicted protein is shown below the sequence and extends from the start of the nuclsotide sequence. The GT repeat KG8 
is in the 3’ untranslated region between 5430 and 5446 bp. 
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scribed microsatelliteKG8(Peral et al., 1994; Snarey et al., 
1994). A polyadenylation signal is present at nucleotides 
5598-5603, and a poly(A) tail was detected in two indepen- 
dent cDNAs (AH4 and AH6) at position 5620. Comparison 
with the cDNAs HG-4 and 1 lBHS21, which are encoded 
by genes in the duplicate 16~13.1 region, show that 1866 
bp at the 5’ end of the currently known PKDl sequence 
lies within the duplicated area. The predicted amino acid 
sequence from the available open reading frame extends 
1614 residues and is shown in Figure 7. A search of the 
SwissProt and NBRF data bases with the available protein 
sequence using the BLAST program (Altschul et al., 1990) 
identified only short regions of similarity (notably, between 
amino acids 690-770 and 1390-l 530) to a diverse group 
of proteins; no highly significant areas of homology were 
recognized. The importance of the short regions of similar- 
ity is unclear, as the search for protein motifs with the 
ProSite program did not identify any recognized functional 
protein domains within the PKDl gene. 
We have presented compelling evidence that mutations 
of the PBP gene give rise to the typical phenotype of 
ADPKD. The location of this gene within the PKDl candi- 
date region and the available genetic evidence from the 
families with mutations show that this is the PKDl gene. 
Four PKDl-associated mutations have been described: a 
de novo translocation, which was subsequently transmit- 
ted with the phenotype; two intragenic deletions (one a 
de novo event); and a splicing defect. The task of identi- 
fying and characterizing the PKDl gene has been more 
difficult than for other disorders because more than three 
quarters of the gene is embedded in a region of DNA that 
is duplicated elsewhere on chromosome 16. This segment 
of 40-50 kb of DNA, present as a single copy in the PKDl 
area (16pl3.3), is reiterated as several divergent copies 
in the more proximal region, 16~13.1. This proximal site 
contains three gene loci (HG-A, HG-B, and HG-C)  that each 
produce polyadenylated mRNAs and share substantial ho- 
mology to the PKDl gene; it is not known whether these 
partially homologous transcripts are translated into func- 
tional proteins. 
Although gene amplification is known as a major mecha- 
nism for creating protein diversity during evolution, the 
discovery of a human disease locus embedded within an 
area duplicated relatively recently is a novel observation. 
In this case, because of the recent nature of the reiteration, 
the whole duplicated genomic region retains a high level 
of homology, not just the exons. The sequence of events 
leading to the duplication and which sequence represents 
the original gene locus are not yet clear. However,  prelimi- 
nary evidence of homology of the 3’ ends of the three HG 
transcripts, which are different from the 3’end of the PKDl 
gene, indicate that the loci in 16~13.1 have probably arisen 
by further reiteration of sequences at this site, after it sepa- 
rated from the distal locus. 
The practical implications of this duplication for isolating 
and characterizing a full-length transcript and for the de- 
tection of PKD7 mutations are considerable. All of the 
cDNA libraries screened contain sequences of the PKDl 
transcript but also of the three similar HG transcripts; care- 
ful comparison of these to the genomic sequence from 
the PKDl region will be required to construct a full-length 
cDNA contig that faithfully represents the entire PKDl 
gene. Screening for mutations within the area duplicated 
is also difficult, whether Southern blotting or a PCR-based 
assay for base pair changes (e.g., single strand conforma- 
tion polymorphism or heteroduplex analysis) is employed. 
In each case the degree of similarity between the duplicate 
regions means that loci from both areas are detected si- 
multaneously, even if an FIT-PCR approach is adopted. 
In such circumstances slight sequence variations between 
the duplicate loci are likely to mask variability due to mu- 
tation. 
Identification of a disease gene does not necessarily 
provide immediate insight into the pathophysiology of a 
disorder. Analysis of the available sequence has not high- 
lighted significant homologies to known proteins, so the 
role of the PKDl protein remains unclear. It is possible 
that characterization of the full protein sequence will shed 
more light on its function. Even the mechanism by which 
the detected mutations cause PKDl is not clear. It has 
previously been argued that PKDl could be recessive at 
the cellular level, with a second somatic mutation required 
to give rise to cystic epithelium (Reeders, 1992). This “two 
hit” process is thought to be the mutational mechanism 
giving rise to several dominant diseases, such as neurofi- 
bromatosis (Legius et al., 1993) and TSC (Green et al., 
1994), that result from a defect in the control of cellular 
growth. If this were the case, however, we might expect 
that a proportion of constitutional PKDl mutations would 
be inactivating deletions as seen in these other disorders. 
Four PKDl mutations have been characterized, and in 
each case an abnormal transcript has been identified by 
Northern analysis or by RT-PCR. Three of these muta- 
tions are effectively internal deletions in the 3’ end of the 
PKDl gene, one of which is a small in-frame deletion. The 
location of these mutations may, however, reflect some 
ascertainment bias as it is this single copy area that has 
been screened most intensively for mutations. Neverthe- 
less, no additional deletions were detected when a large 
part of the gene was screened by FIGE, and studies by 
PFGE showed no large deletions of this area in 75 PKDl 
patients. It is possible that the mutations detected so far 
result in the production of an abnormal protein that causes 
disease through a gain of function. However,  it is also 
possible that these mutations eliminate the production of 
functional protein from this chromosome and result in the 
PKD7 phenotype by haploinsufficiency or only after loss 
of the second PKDl homolog by somatic mutation. Clearly, 
a larger number of mutations need to be studied and the 
5’ end of the gene located and characterized before the 
full spectrum of PKDl mutations can be accessed. 
One mutation that probably deletes the entire PKD7 
gene has been identified (WS-53), but in this case it also 
disrupts the adjacent TSCPgene, and the resulting pheno- 
type is of TSC with severe cystic kidney disease. Renal 
cysts are common in TSC so that the phenotypic signifi- 
cance of deletion of the PKD7 gene in this case is difficult 
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to assess. It is clear that not all cases of renal cystic dis- 
ease in TSC are due to disruption of the PKDl gene; chro- 
mosome g-linked TSC (TSC7) families also manifest cystic 
kidneys, and we have analyzed many TSC2 patients with 
kidney cysts who do not have deletion of the PKDl gene. 
A number of patients with TSC and severe cystic kidney 
disease are presently being analyzed in detail to see 
whether they also involve disruption of the PKD7 gene. 
Familial studies indicate that de novo mutations proba- 
bly account for only a small minority of all ADPKD cases; 
a recent study detected five possible spontaneous muta- 
tions in 209 families (Davies et al., 1991). However,  in our 
study 1 of 3 intragenic mutations detected was a novel 
mutation, and the PKD7-associated translocation was also 
a de novo event. Furthermore, the mutations detected in 
the two familial cases do not account for a significant pro- 
portion of the local PKD7. The OX875 deletion was only 
detected in 1 of 282 unrelated cases, and the splicing 
defect was seen in only 1 of 48 unrelated cases. Neverthe- 
less, studies of linkage disequilibrium have found evi- 
dence of common haplotypes associated with PKD7 in a 
proportion of some populations (Peral et al., 1994; Snarey 
et al., 1994), suggesting that common mutations will be 
identified. 
Once a larger range of mutations has been character- 
ized, it will be possible to evaluate whether the type and 
location of mutation determines disease severity and 
whether there is a correlation between mutation and extra- 
renal manifestations. Previous studies have provided 
some evidence that the risk of cerebral aneurysms “runs 
true” in families (Huston et al., 1993) and that some PKD7 
families exhibit a consistently mild phenotype (Rnnanen 
et al., 1987). A recent study has concluded that there is 
evidence of anticipation in ADPKD families, especially if 
the disease is transmitted through the mother (Fink et al., 
1994). Furthermore, analysis of families with early mani- 
festation of ADPKD show that there is a significant intra- 
familial recurrence risk and that childhood cases are most 
often transmitted maternally (Fink et al., 1993; Zerres et 
al., 1993). This pattern of inheritence is reminiscent of 
that seen in diseases in which an expanded trinucleotide 
repeat was found to be the mutational mechanism (re- 
viewed by Mandel, 1993). However,  no evidence for an 
expanding repeat correlating with PKDl has been found 
in this region, although such a sequence cannot be ex- 
cluded. 
There is ample evidence that early presymptomatic di- 
agnosis of PKD7 is helpful because it allows complications 
such as hypertension and urinary tract infections to be 
monitored and treated quickly (Ravine et al., 1991). The 
identification of mutations within a family will allow rapid 
screening of that and other families with the same muta- 
tion. Given the difficulties of identifying mutations in this 
region, however, genetic linkage analysis is likely to re- 
main important for presymptomatic diagnosis. The accu- 
racy and ease of l inkage-based diagnosis will be improved 
by the identification of the PKD7 gene: a microsatellite lies 
in the S’untranslated region of this gene (KG8), and several 
CA repeats are located 5’ of the gene (see Figures 1 a and 
6; Peral et al., 1994; Snarey et al., 1994). 
The identification of the PKDl gene is a first step toward 
understanding the molecular pathology of this complex 
disorder. Characterization of a full-length transcript and 
definition of the full range of mutations that cause PKD7 
are now required, progress that is likely to be impeded 
because this area isduplicated. The information now avail- 
able will, however, allow study of the PKDl protein to deter- 
mine both its normal role in the cell and the mechanism 
by which mutation of the PKDl gene causes the major 
renal cystic disease in humans. 
Experimental Procedures 
Clinical Details of Patlents 
Family 77 
Patients 77-2 and 77-3 are 48 and 17 years old, respectively, and have 
typical ADPKD. Both have bilateral polycystic kidneys, and 77-2 has 
impaired renal function. Neither patient manifests any signs of TSC 
(apart from cystic kidneys) on clinical and ophthalmological examina- 
tion or by a computerized tomography scan of the brain. 
Patient 77-4 is 13 years old and severely mentally retarded and has 
multiple signs of TSC, including adenoma sebaceum, depigmented 
macules, and periventricular calcification on computerized tomogra- 
phy scan. Renal ultrasound reveals a small number of bilateral renal 
cysts. 
ADPKD Pat/en& 
Patient 0X875, age 48, developed ESRD from ADPKD. Progressive 
decline in renal function has been observed over 17 years; ultrasound 
examinations documented enlarging polycystic kidneys with less ex- 
tensive hepatic cystic disease. Both kidneys were removed after renal 
transplantation, and pathological examination showed typical ad- 
vanced cystic disease in kidneys weighing 1920 g and 3450 g (normal 
average, 120 g). 
Patient OX1 14, age 54, developed ESRD from ADPKD: diagnosis 
was made by radiological investigation during an episode of abdominal 
pain at age 25. A progressive decline in renal function and the develop- 
ment of hypertension were subsequently observed. Ultrasonic exami- 
nation demonstrated enlarged kidneys with typical cystic disease, with 
less severe hepatic involvement. 
Patient OX32 is a member of a large kindred affected by typical 
ADPKD in which several members have developed ESRD. The patient 
himself has been observed for 12 years, with progressive renal fail- 
ure and hypertension following ultrasonic demonstration of polycystic 
kidneys. 
No signs of TSC were observed on clinical examination of any of 
the ADPKD patients. 
DNA Electrophoretls and Hybridkatlon 
DNA extraction, restriction digests, electrophoresis, Southern blotting, 
hybridization, and washing were performed by standard methods or 
as previously described (Harris et al., 1990). FIGE was performed with 
the Bio-Rad FIGE mapper using program 5 to separate fragments 
from 25-50 kb. High molecular weight DNA for PFGE was isolated in 
agarose blocks and separated on the Bit-Rad CHEF DRII apparatus 
using appropriate conditions. 
Genomlc DNA Probes and Somatic Cell Hybrids 
Many of the DNA probes used in this study have been described pre- 
viously: MS2052(D76S309; Royle et al., 1992); GGG7 (D16S259; Ger- 
mino et al., 1990); N54 (D76S139; Himmelbauer et al., 1991); and 
SM6 (D76S665), CW23, CW27, and J/f7 (European Chromosome 16 
TuberousSclerosisConsortium, 1993). Microsatelliteprobesfor haplo- 
type analysis were KG6 and W5.2 (Snarey et al., 1994); SM6, CW3, 
and CW2 (Peral et al., 1994); 76AC2.5 (Thompson et al., 1992); SM7 
(Harris et al., 1991); and VK5AC (Aksentijevich et al., 1993). 
Probes isolated during this study were JH4, JH5, and JH6 (11 kb, 
6 kb, and 6 kb BamHl fragments, respectively) and JH73 and JH74 
(4 kb and 2.8 kb BarnHI-EcoRI fragments, respectively), all from the 
cosmid JH2A; JH8 and JH70 are 4.5 kb and 2 kb Sacl fragments, 
respectively, and J/f72 is a 0.8 Sacl-BamHI fragment, all from JH4; 
6S7 and 6S3 are 2.4 kb and 0.6 kb Sacll fragments, respectively, from 
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JH8; CWlO is a 0.5 kb Notl-Mlul fragment of SM25A; JH17 is a 2 kb 
EcoRl fragment of MM1 7. 
The somatic cell hybrids N-OH1 (Germino et al., 1990) P-MWH2A 
(European Chromosome 18 Tuberous Sclerosis Consortium, 1993) 
and Hy145.19 (Himmelbauer et al., 1991) have previously been de- 
scribed. Somatic cell hybrids containing the paternally derived (BP2- 
10) and maternally derived (BPS9) chromosomes from OX1 14 were 
produced by the method of Deisseroth and Hendrick (1979). 
Constructing a Cosmid Contlg 
Cosmids were isolated from chromosome i&specific and total geno- 
mic libraries, and a contig was constructed using the methods and 
libraries previously described (European Chromosome 16 Tuberous 
Sclerosis Consortium, 1993). To ensure that cosmids were derived 
from the 18~13.3 region (not the duplicate 16~13.1 area), initially 
probes from the single copy area were used to screen libraries (e.g., 
CW21 and N54). Two cosmids mapped entirely within the area dupli- 
cated, CWlO/// and JC10.28. To establish that these were from the 
fKD1 area, they were restriction mapped and hybridized with the probe 
CWlO. The fragment sizes detected were compared with results ob- 
tained with hybrids containing only the 16~13.3 area (Hy145.19) or 
only the 16~13.1 region (PMWH2A). 
FISH 
FISH was performed essentially as previously described (Buckle and 
Rack, 1993). The hybridization mixture contained 100 ng of biotin II- 
dUTP-labeled cosmid DNA and 2.5 ug of human Cot-l DNA (Bethesda 
Research Laboratories), which was denatured and annealed at 37OC 
for 15 min prior to hybridization at 42OC overnight. After stringent 
washes, the site of hybridization was detected with successive layers 
of fluorescein-conjugated avidin (5 ug/ml) and biotinylated anti-avidin 
(5 uglml) (Vector Laboratories). Slides were mounted in Vectashield 
(Vector Laboratories) containing 1 @ml propidium iodide and 1 ugl 
ml 4’,6’-diamidino-2-phenylindole (DAPI) to allow concurrent G-banded 
analysis under UV light. Results were analyzed and images captured 
using a Bio-Rad MRC 600 confocal laser scanning microscope. 
cDNA Screening and Characterization 
Fetal brain cDNA libraries in I. phage (Clonetech; Stratagene) were 
screened by standard methods with genomic fragments in the single 
copy area (equivalent to CW23 and CW21) or with a 0.8 kb Pvull-EcoRI 
single copy fragment of AH3. Six PBP cDNAs were characterized, 
including two previously described cDNAs, AH4 (1.7 kb) and 3A3 (2.0 
kb) (European Chromosome 16 Tuberous Sclerosis Consortium, 
1993) and four novel cDNAs, AH3 (2.2 kb), AH6 (2.0 kb), AlC (2.2 
kb), and B1.E (2.9 kb). A Striatum library (Stratagene) was screened 
with JH4, and an HG-C cDNA, llBH.927 (3.8 kb), was isolated; 21P.9 
is a 0.9 kb Pvull-EcoRI subclone of this cDNA. A HG-A or /-/G-B cDNA, 
HG-4 (7 kb), was also isolated by screening the fetal brain library (Stra- 
tagene) with JH8. HG-4/l. 1 is a 1 .l kb Pvull-EcoRI fragment from the 
3’ end of HG-4. lAlH.6 is a 0.6 kb Hindlll-EcoRI subclone of a TX2 
cDNA, lA-1 (1.7 kb), which was isolated from the Clonetech library. 
Each cDNA was subcloned into Bluescript and sequenced utilizing a 
combination of sequential truncation and oligonucleotide primers us- 
ing DyeDeoxy’ Terminators (Applied Biosystems) and an ABI 373A 
DNA Sequencer (Applied Biosystems) or by hand with Sequenase T7 
DNA polymerase (U. S. Biochemicals). 
RNA Procedures 
Total RNA was isolated from cell lines and tissues by the method of 
Chomczynski and Sacchi (1987) and enrichment for mRNA was made 
using the poly(AT) tract mRNA isolation system (Promega). For RNA 
electrophoresis, 0.5% agarose denaturing formaldehyde gels were 
used that were Northern blotted, hybridized, and washed using stan- 
dard procedures. The 0.24-9.5 kb RNA (GIBCO BRL) size standard 
was used, and hybridization of the probe (l-983) to the 13 kb utrophin 
transcript (Love et al., 1989) in total fibroblast RNA was used as a size 
marker for the large transcripts. 
RT-PCR was performed with 2.5 pg of total RNA by the method 
of Brown et al. (1990) with random hexamer primers, except that AMV 
reverse transcriptase (Life Sciences) was employed. To characterize 
the deletion of the PBP transcript in OX1 14, we used the following 
primers: AH3F9, S-m GAC AAG CAC ATC TGG CTC TC-3’; AH3B7. 
5’-TAC ACC AGG AGG CTC CGC AG-3’. These were emplyed In a 
DMSO-containing PCR buffer (Dade et al., 1990) with 0.5 mM MgCI, 
and 38 cycles of 94OC for 1 min, 81°C for 1 min, and 72OC for 2 min 
plus a final extension of IO min. 
The 3A3 C primers used to amplify the cDNA from OX32 and DNA 
were these: 3A3 Cl, 5’CGC CGC lTC ACT AGC TTC GAC-3’; 3A3 
C2, 5’-ACG CTC CAG AGG GAG TCC AC-3’. These were employed 
in a PCR buffer and cycle previously described (Harris et al., 1991) 
with 1 mM MgCk and an annealing temperature of 61OC. 
PCR products for sequencing were amplified with Pful (Stratagene) 
and ligated into the Srfl site in PCR-Script (Stratagene) in the presence 
of Srfl. 
RNAase Protection 
Tissues from normal and end stage polycystic kidneys were immedi- 
ately homogenized in guanidinium thiocyanate. RNA was purified on 
a cesium chloride gradient, and 30 ug of total RNA was assayed by 
RNAase protection by the method of Melton et al. (1984) using a geno- 
mic template generated with the 3A3 C primers. 
Heteroduplex Analysis 
Heteroduplex analysis was performed essentially as described by 
Keen et al. (1991). Samples were amplified from genomic DNA with 
the 3A3 C primers, heated at 95OC for 5 min, and incubated at room 
temperature for at least 30 min before loading on a Hydrolink gel (AT 
Biochem). Hydrolink gels were run for 12-I 8 hr at 250 V and fragments 
observed after staining with ethidium bromide. 
Extraction and Amplification of Paraffln-Embedded DNA 
DNA from formalin-fixed, paraffin wax-embedded kidney tissue was 
prepared by the method of Wright and Manos (1990) except that after 
proteinase K digestion overnight at 55OC, the DNA was extracted with 
phenol plus chloroform before ethanol precipitation. Approximately 50 
ng of DNA was used for PCR with 1.5 mM MgCb and 40 cycles of 
94OC for 1 min, 59OC for 1 min, and 72OC for 40 s, plus a 10 min 
extension at 72OC. 
Theoligonucleotideprimersdesigned toamplifyacrossthegenomic 
deletion of OX875 were as follows: AH4F2, 5’-GGG CAA GGG AGG 
ATG ACA AG-3’; JHl4B3, 5’-GGG l-l-r ATC AGC AGC AAG CGG-3’. 
These produced a product of -220 bp in individuals with the OX875 
deletion. 
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